The Spanish biotech buys the Swiss diagnostic company specialised in precision medicine. Link to their website.More information
Our fetal DNA test detects chromosomal aneuploidies and deletions, as well as punctual variants in the DNA sequence.More information
NIMGenetics offers support services to the research and pharmaceutical industry with high quality standards and certifications.More information
At NIMGenetics we offer specialists the sequencing of specific gene panels or the entire exome through ExoNIM® and NIMSeq®.More information
GenoNIM®, our Whole Genome Sequencing (WGS) service, allows the joint identification of changes in the genomic and mitochondrial DNA sequence.More information
NIMGenetics is a Spanish biotechnology multinational that specialises in designing and selling clinical genetic diagnostic products and services. We develop exclusive genomic products based on two types of technology: microarrays and massive parallel sequencing.
NIMGenetics is a one-stop solution that supports specialists at all stages of the diagnostic process by providing comprehensive genetic approaches and all the pre- and post-testing assistance they could need. And always following strict Quality standards.
Our aim is to provide medical specialists with the best genetic testing tools, as well as our extensive knowledge of the human genome to help improve the health of patients with genetic diseases, as well as their quality of life and that of their families.
In addition to Spain, NIMGenetics also currently operates in Portugal, Mexico and Brazil, with a team of highly qualified geneticists. We also have partners in Europe, Latin America and the United States.
At NIMGenetics, we support specialists at all stages of the clinical diagnostic process by providing comprehensive genetic approaches and offering all the pre- and post-testing assistance that professionals could need in order to help their patients receive more precise diagnoses and advice.
Specialists in non-invasive prenatal screening thanks to TrisoNIM, as well as in genetic risk and hereditary thrombophilia tests.
We use different approaches that give us more scope to adapt to clinical and patient needs, with a high degree of personalisation and flexibility.
We offer you the latest early gynaecological cancer detection technologies, thanks to our molecular screening tests.
NIMGenetics offers everything from conventional tests to the most advanced array CGH and NGS panel technologies in order to guide specialists towards the most appropriate treatment and clinical management of cancer.
For a comprehensive approach to these pathologies, we offer the sequential combination of different genetic tests, personalised to each patient.
We offer different approaches using massive parallel sequencing, among others, to help diagnose this family of diseases, with a special focus on the genetic approach to epilepsy.
NIMGenetics offers cutting-edge genomic technologies to diagnose ophthalmological diseases, which, together with genetic counselling, can improve the quality of life of those with genetic eye diseases.
We offer research support services with high-quality standards and certifications, thanks to our cutting-edge technology and team of experts.
We offer healthcare professionals a wide range of COVID products, as well as complete molecular karyotyping kits for internal analysis by hospital laboratories.
First to transfer cutting-edge genomic technologies to clinical practice.
We have been recognised and awarded for our excellence in the way we work with specialists and for patients. More information.
Extensive test portfolio for a complete genetic approach adapted to the patient.
Our company is accredited by international organisations that work to ensure the quality of molecular genetic and cytogenetic processes. More information.
Over 300 international publications and more than 50,000 genetic tests carried out. More information.
Immediate access to our team of experts, active members of scientific associations of vital importance in the field of genetic-clinical diagnosis.